.pyc is as much as a peer to obd, as fiat is to Ferrari. Obd have only been going 2 years, so low revenues are expected, but they already have 13 million assets, patents, fda approval, us customers. ..pyc have only 300k assets, run at a loss for over a decade, no patents, no fda approval, barely any customers, and have just declared a mere 79k 6 month revenue. But desperate Jack thinks they should be the same share price.

And Jack, Merck is already a customer of pyc.....so when they do 270 revenue in a year for example, 150k of that could be what Merck already do. So when the contract says it's worth £450 grand, it's not on top of what they are already spending, it will be including it, so it would turn out an extra 300k revenue, though obviously operating costs will increase along side increased revenues also.

Perfectly relaxed, SS1 perhaps you should have taken that advice yourself when you sold out because of Daveavt talking it down only to continue to hang around the boards - surely you have better things to do with your time than hang around here.

Relax mate. This is bound to settle between news. Who knows what the next contract will bring. Just switch off from here if contrarian views annoy you. The sp will speak for itself. Atm it's settling due to lack of news Imo.

One of the best ways to establish what that fair value is, is to compare PYC to a peer. In this case that peer is Oxford Bio Dynamics (OBD). OBD has a similar client base (although 7 VS PYC's 2, but PYC is in discussions and that 2 is growing), has a similar product (both have proprietary bio-simulation technology for bio markers), and OBD receives similar revenues for the contracts they have with their clients (check OBD's recent annual report VS PYC's recent RNS').

OBD has a mcap of ca.GBP180M and PYC has a mcap of GBP5M. OBD's has ca.GBP13M of that in assets of which ca.GBP12M is in cash. Cash is not valued at multiples thus if that were to be taken off the mcap as is, it would leave OBD's mcap at ca.GBP168M for essentially the same as what PYC has with the exception of OBD having 5 more large pharma clients - we know PYC is in active discussions with large pharmas thus that gap is in the process of closing.

However even accounting for this it still leaves an extremely large gulf between what OBD is valued at VS PYC.

"Announcement that the Company had entered into a Master Services Agreement with Merck whose value to Physiomics in calendar 2018 is expected to be £500k" - meaning none of the Merck contract is in the last set of results thus second half of the financial year (first half 2018) all things being equal, we should see 250K from this 70K and 35K contracts announced - it was stated in the RNS that both would complete in the current financial year. Minimum revenue for second half of the financial year should therefore be 305K VS FY 2017 of 270K. Thus in the second half alone we will make more than the entire full year 2017.

"The Company is focused on expanding its pipeline of customers and significantly growing the business"

coupled with;

"We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process. We further believe that there will be increased acceptance of the value of modelling the effects of oncology treatments rather than falling back on more traditional, often heuristic, methods."

demonstrates that there is a high likelihood of more contracts yet to come.

This view if further strengthened by;

"We believe that Physiomics offers some of the most advanced and thoroughly validated models in this field and expect that endorsement of the technology by a world class pharmaceutical company like Merck KGaA will encourage others to follow. We are now seeing the first signs of this with the recently announced contracts signed with two other major pharmaceutical companies."

note they say the first signs, indicating there is more yet to come and this is just the beginning.

Those additional successes could well come from;

"A combination of long term business development initiatives and the halo effect of recent announcements has led to a significant expansion of our business development pipeline amongst both small and large potential clients. This is reflected in our announcement, in January, of our first new major pharmaceutical client for several years."

Much more to come here and whats to come is only going to be bigger and better than ever before as the tech has been refined, validated and the industry is also turning a corner with increased adoption. Somewhat a perfect storm situation given PYC have some of the most advanced models in the field

"Announcement that the Company had entered into a Master Services Agreement with Merck whose value to Physiomics in calendar 2018 is expected to be £500k" - meaning none of the Merck contract is in the last set of results thus second half of the financial year (first half 2018) all things being equal, we should see 250K from this 70K and 35K contracts announced - it was stated in the RNS that both would complete in the current financial year. Minimum revenue for second half of the financial year should therefore be 305K VS FY 2017 of 270K. Thus in the second half alone we will make more than the entire full year 2017.

"The Company is focused on expanding its pipeline of customers and significantly growing the business"

coupled with;

"We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process. We further believe that there will be increased acceptance of the value of modelling the effects of oncology treatments rather than falling back on more traditional, often heuristic, methods."

demonstrates that there is a high likelihood of more contracts yet to come.

This view if further strengthened by;

"We believe that Physiomics offers some of the most advanced and thoroughly validated models in this field and expect that endorsement of the technology by a world class pharmaceutical company like Merck KGaA will encourage others to follow. We are now seeing the first signs of this with the recently announced contracts signed with two other major pharmaceutical companies."

note they say the first signs, indicating there is more yet to come and this is just the beginning.

Those additional successes could well come from;

"A combination of long term business development initiatives and the halo effect of recent announcements has led to a significant expansion of our business development pipeline amongst both small and large potential clients. This is reflected in our announcement, in January, of our first new major pharmaceutical client for several years."

Much more to come here and whats to come is only going to be bigger and better than ever before as the tech has been refined, validated and the industry is also turning a corner with increased adoption. Somewhat a perfect storm situation given PYC have some of the most advanced models in the field

And yet here we are Jack, on a downward trend to where we said the price would lead to. This is the thing Jack, you can think you're right as much as you like, but the price, and the market don't agree with you.

Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.

This site requires cookies in order to give you the best user experience. By using this site, you are agreeing to the use of cookies.